Skip to main content
. 2020 Jan 2;43(4):107–120. doi: 10.1097/CJI.0000000000000307

FIGURE 2.

FIGURE 2

Cytotoxic function and cytokine production of chimeric antigen receptor (CAR) T cells were not affected by Bruton tyrosine kinase inhibitor when stimulated with CD19+ tumor cells. A, Target cell numbers normalized to time 0, from triplicate wells without CAR T cells with ibrutinib or acalabrutinib (mean±SEM). Representative images show red target cells at day 0 and day 4 of treatment. Absolute (Abs) change in cytokine concentration compared with untreated controls of interferon-gamma (IFN-γ), interleukin 2 (IL-2), and tumor necrosis factor-alpha (TNF-α) 2 days after stimulation with target cells at an effector:target ratio of 2.5:1 and ibrutinib (B) or acalabrutinib (C). Data from 2 independent experiments and 3 CAR T-cell donors (mean±SEM). Statistical significance from each donor indicated for acalabrutinib 5000 nM and ibrutinib 500 nM. D, Target cell numbers (effector:target ratio, 2.5:1) normalized to time 0, from triplicate wells cocultured with CAR T cells with ibrutinib or acalabrutinib (mean±SEM). Representative images show red target cells on day 4 of the cytotoxic assay. E, Dose effect of ibrutinib or acalabrutinib on cytolytic activity (effector:target ratio, 2.5:1) of CAR T cells, normalized to untreated control (100). Data from 3 independent experiments and 3 CAR T-cell donors (mean±SEM). Statistically significant differences are indicated as *P<0.05, **P<0.01, ***P<0.001, and ****P<0.0001.